Pulmatrix Historical Cash Flow
| PULM Stock | USD 6.12 0.01 0.16% |
Analysis of Pulmatrix cash flow over time is an excellent tool to project Pulmatrix future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 7.6 K or End Period Cash Flow of 21 M as it is a great indicator of Pulmatrix ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Pulmatrix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pulmatrix is a good buy for the upcoming year.
Pulmatrix |
About Pulmatrix Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Pulmatrix balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Pulmatrix's non-liquid assets can be easily converted into cash.
Pulmatrix Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Pulmatrix's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Pulmatrix current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.At this time, Pulmatrix's Change To Account Receivables is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 3.6M | 4.9M | 8K | 7.6K | Depreciation | 1.2M | 1.5M | 1.5M | 1.5M |
Pulmatrix cash flow statement Correlations
Click cells to compare fundamentals
Pulmatrix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pulmatrix cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Free Cash Flow | 3.2M | (12.8M) | (19.9M) | (19.4M) | (16.7M) | (15.8M) | |
| Other Cashflows From Financing Activities | 160K | 13.7M | 9.6M | (152K) | (676K) | (642.2K) | |
| Capital Expenditures | 58K | 281K | 144K | 86K | 676K | 709.8K | |
| Total Cash From Operating Activities | 3.2M | (12.5M) | (19.7M) | (19.4M) | (16.0M) | (15.2M) | |
| Net Income | (20.6M) | (19.3M) | (20.2M) | (18.8M) | (14.1M) | (14.8M) | |
| Total Cash From Financing Activities | 17.7M | 21.0M | 43.5M | 1.2M | 53K | 50.4K | |
| Change In Cash | 20.9M | 8.2M | 23.6M | (18.2M) | (16.6M) | (15.8M) | |
| Stock Based Compensation | 3.0M | 2.1M | 1.2M | 1.1M | 954K | 906.3K | |
| Change In Working Capital | 13.7M | (4.7M) | (5.5M) | (3.2M) | (4.3M) | (4.1M) | |
| Depreciation | 765K | 1.0M | 1.2M | 1.5M | 1.5M | 1.5M | |
| Other Non Cash Items | 7.3M | 9.3M | 3.6M | 4.9M | 8K | 7.6K | |
| End Period Cash Flow | 23.6M | 31.9M | 55.5M | 37.3M | 20.6M | 21.0M | |
| Begin Period Cash Flow | 2.8M | 23.6M | 31.9M | 55.5M | 37.3M | 39.1M | |
| Sale Purchase Of Stock | 19.3M | 17.7M | 21.0M | (152K) | (174.8K) | (166.1K) | |
| Total Cashflows From Investing Activities | (58K) | (281K) | (144K) | (86K) | (77.4K) | (73.5K) | |
| Cash And Cash Equivalents Changes | (632K) | (987K) | 20.9M | 8.2M | 9.4M | 9.9M | |
| Cash Flows Other Operating | 30K | 16K | (82K) | 9.5M | 10.9M | 11.4M | |
| Change To Operating Activities | 220K | (1.1M) | (2.1M) | (1.6M) | (1.5M) | (1.4M) | |
| Change To Netincome | 9.3M | 10.4M | 4.7M | 1.1M | 1.0M | 952.5K | |
| Change To Liabilities | 21.6M | (10.7M) | (3.5M) | (336K) | (302.4K) | (287.3K) | |
| Investments | (58K) | (281K) | (144K) | (86K) | (380K) | (361K) | |
| Issuance Of Capital Stock | 17.5M | 7.3M | 43.3M | 1.4M | 53K | 50.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.